News & Updates

Once-daily application of tapinarof cream 1% significantly improves the Eczema Area Severity Index (EASI) score in patients with atopic dermatitis (AD), regardless of their disease severity or age, according to the pivotal phase III ADORING 1 and 2 trials presented at AAAAI 2024.

Use of potentially inappropriate medications (PIM) is common among frail older adults, suggesting the need for improvement to increase pharmacotherapy safety in these individuals, reports a study.

A recent study has found inconsistencies in the use of ketamine, particularly in terms of dose, duration, and reasons to avoid or limit this medication. This is the case despite many critical care practitioners reporting being comfortable in using ketamine.

For patients undergoing coronary angioplasty for in-stent restenosis, a paclitaxel-coated balloon significantly lowers the incidence of target lesion failure compared with an uncoated balloon, according to the results of the multicentre AGENT IDE trial.

Treatment with zoledronate leads to reduced fracture rates, with the protective benefit persisting for 1.5 to 3.5 years after the final dose, as reported in the extension phase of a study.

Ruxolitinib cream, a topically administered selective Janus kinase 1/2 inhibitor, appears to be effective for mild-to-moderate atopic dermatitis (AD) in children aged 2–11 years, according to the TRuE-AD3 trial presented at AAAAI 2024.

Benralizumab compares favourably with mepolizumab for inducing remission in adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA), as shown in the results of the head-to-head phase III MANDARA trial.